Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2022 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
September 26, 2022 07:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
September 12, 2022 21:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
September 12, 2022 07:00 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
September 11, 2022 09:45 ET | Source: Relay Therapeutics, Inc.

Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose Enrollment for the pivotal...
August 18, 2022 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress

CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
August 04, 2022 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4008 at June...
July 28, 2022 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
June 27, 2022 06:00 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma...
June 16, 2022 07:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event

CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...